Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Processa Pharmaceuticals Inc
PCSA
Healthcare
Biotechnology
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC...
treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PCSA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 26, 2024 9:04am
New Press Release - Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
read article.
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 25, 2024 4:06pm
RE:RE:RE:PCSA..... go ahead .... I dare ya to Chase !
Market closed....PCSA closed nice eh ? I guess AH will be a big "Nothing Burger"....cause the pump happened during the last 20 mins of reg hrs trading C u all 2morrow ....it's Fryday
...more
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 25, 2024 3:41pm
RE:RE:PCSA..... go ahead .... I dare ya to Chase !
R ya still watching ....what's it at now....20 mins til close.....Here is my prediction for AH : P & D......short and sweet Then the P.O announcement....just what all the Bears are waiting
...more
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 25, 2024 3:13pm
RE:PCSA..... go ahead .... I dare ya to Chase !
Power Hour pop ....just in time to lure some Greater Fools in some more Go ahead ....I dare ya....$4.50
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 25, 2024 2:17pm
RE:RE:PCSA..... go ahead .... I dare ya to Chase !
Sub $4 now Just giving you the update ; )
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 25, 2024 1:07pm
RE:PCSA..... go ahead .... I dare ya to Chase !
What did I tell all u maddapakkas..... $4.20 again wait for the rug pull ....it's comin
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2024 1:02pm
PCSA..... go ahead .... I dare ya to Chase !
It's Fryday ...don't ya know
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 25, 2024 12:02pm
RE:RE:PCSA....How am I doing so far SH audience?????
Still no comments from the SH Audience....sheesh ...your a tough crowd to please ; ) PCSA just tapped $4.23
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 25, 2024 11:56am
RE:PCSA....How am I doing so far SH audience?????
Just tapped $4.46 No comments from the SH Audience ; )
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2024 11:21am
PCSA....How am I doing so far SH audience?????
This is going to get real "funky"....keep watching
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2024 10:03am
PCSA....Here is why there is all this vol & price action...
currently trading at $5.58. There is going to be a P.O....guaranteed ; ) Read this: https://www.sec.gov/Archives/edgar/data/1533743/000149315224003101/forms-1a.htm
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2024 9:45am
PCSA.....recent RS...now the pump.....Guess what?
It's Fryday......This a.m's action is just the "grease in the frying pan" You will all get Fried on Fryday Cheers !
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 13, 2023 1:40pm
New Press Release - Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
Hanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023. Mr. Thompson served on our Board of Directors since we were formed in 2017 and was...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 09, 2023 8:15am
New Press Release - Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 01, 2023 8:15am
New Press Release - Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-CapHANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...
read article.
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Why Dozens of Pro Athletes are Paying Attention to this Product
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
Learn How this Company is Disrupting Point-of-Care Testing